Patient deaths, FDA hold cloud Unum’s $86M IPO bid

Unum Therapeutics logo
Unum's immunotherapies are designed to pack a double punch against cancer when administered alongside antibodies like rituximab. (Unum Therapeutics)

Cancer immunotherapy company, Unum Therapeutics, filed with the SEC Friday to raise up to $86 million in its IPO. But the biotech revealed more than its desire for capital in its filing: It revealed a clinical hold on, and two patient deaths in, a phase 1 trial in non-Hodgkin's lymphoma.

The candidate, ACTR087, was being tested in combination with rituximab in patients with CD20+ B cell-relapsed or refractory non-Hodgkin's lymphoma. The company observed “ACTR087-related serious adverse events, including two patient deaths” in the trial, which led to the FDA halting the trial pending certain information, Unum said in its form S-1.

The FDA lifted the hold last month, Unum said, but the Cambridge, Massachusetts-based biotech kept mum on the hold and patient deaths while prepping for the IPO. It filed confidentially in November.


Share your opinion. Take our five minute survey.

How do you select the most suitable advanced dosage forms for new molecules in your development pipelines? Share your insights in this 5-minute survey. The first 50 qualified respondents will receive a $5 Amazon gift card.

Unum’s pipeline is based on its Antibody-Coupled T-cell Receptor, or ACTR, platform. T cells, are modified to express ACTR, a chimeric protein that gives them the ability to bind to tumor-targeting antibodies. When the engineered T cells are reinfused into the patient alongside antibodies like rituximab, they are expected to unleash a heightened tumor-fighting response.

RELATED: FierceBiotech’s 2015 Fierce 15Unum Therapeutics

Its lead candidate, ACTR087, was given to patients in two doses in the phase 1 trial. Of the six patients in the lower-dose arm with evaluable data, two had complete responses to the treatment and one had a partial response. No adverse events were reported.

But in the nine-patient, higher-dose group, there were “dose-limiting toxicities in three patients.” Two deaths were directly tied to ACTR087—the patients developed severe cytokine release syndrome, a frequent side effect of CAR-T therapies that can be fatal. The third patient died from ACTR087-related neurotoxicity.

“[No] conclusions regarding the efficacy of ACTR087 can yet be drawn and no head-to-head trials have been conducted that would enable us to make a direct safety and efficacy comparison,” Unum said in the SEC filing. But it is already comparing the treatment with Yescarta and Kymriah, the CAR-T therapies that scored FDA approval last year for blood cancers. The response rate in the lower-dose group are similar to those reported for Yescarta and Kymriah, at 39% and 32% complete response rates, respectively.

Suggested Articles

Boston Scientific’s deep brain stimulation implant for treating Parkinson’s disease has been approved by the FDA as safe to use within an MRI.

Sarepta will negotiate a warning for golodirsen rather than carry out more studies. But the implications of the rejection range beyond golodirsen.

The Pfizer Foundation has awarded 20 grants to organizations involved in tackling infectious diseases in low- and middle-income countries.